Royalty Report: Drugs, Cancer, Vaccine – Collection: 209514

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Vaccine
  • Immune
  • HPV
  • Disease
  • Wound Care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 209514

License Grant
For new inventions, other than incremental improvements which are dominated by existing patents or pending patent applications for which Sponsor holds a license, the University Licensor grants to Sponsor Licensee, an option to secure an exclusive license, including the right to grant sublicenses.

For inventions which are incremental improvements dominated by existing patents or pending patent applications for which Sponsor holds a license,  Licensor grants to Sponsor an option to secure an exclusive license with the right to make, use and sell, have made, have used, import and offer for sale the claimed invention conceived or reduced to practice in the conduct of the Project.

The Licensor retains a perpetual, non-exclusive right to use the licensed property, product, procedure or process and to use the licensed technology for basic and clinical research, and the educational purposes of the Licensor, and not for any commercial purpose.

License Property
The Licensed Product means any method, procedure, process, product, or component part thereof conceived or developed by Licensor in the conduct of the Project whose manufacture, sale, use, importation, or offer for sale is covered by the claim of a pending patent application or which could be construed to infringe the licensed patent in the absence of the license.

The knowledge is relating to a project entitled 'Use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases'.

Heat shock proteins, also known as HSPs, are also called stress proteins. HSPs are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation. HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms. Under normal conditions, heat shock proteins play a major role in transporting fragments of proteins called peptides, including antigenic peptides, within a cell, and are thus called “chaperones.” Antigenic peptides are those portions of a protein that stimulate immune response when recognized by the immune system. Because HSPs chaperone peptides within the cell, they bind a broad array of antigenic peptides and facilitate their recognition by the immune system. Thus, HSPs help present the antigenic “fingerprint” of the cell to the immune system.

Field of Use
This agreement is for the immunology field.

IPSCIO Record ID: 110461

License Grant
The University grants to Licensee and its Affiliates the exclusive license in the Territory with the right to grant sublicenses to others, under the Patent Rights, to make, have made, use, sell, import and offer for sale Products and to practice Processes.

Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.

License Property
The licensed patent applications relate to a Modified Heat Shock Protein-Antigenic Peptide Complex.
Field of Use
The licensed patent is in the area of the use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases (the 'Field').

IPSCIO Record ID: 189409

License Grant
Licensor hereby grants to the Licensee, a subsidiary, an exclusive worldwide license with the right to sublicense others, to make, have made, use, sell and lease the Products described in the Licensed Patent Rights with reach-through rights reserved to Licensor.
License Property
The license is for Patent Application Serial No. 62/478532, titled as Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization and commercially named StemVacs.

The patent describes methods of cancer treatment through the administration of proteins or specific peptides found on tumor stem cells in vivo, in a manner eliciting monocyte or dendritic cell migration in order to allow uptake of proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor initiating stem cells.

Field of Use
This agreement is for the vaccine industry.

IPSCIO Record ID: 364010

License Grant
Licensor hereby grants to Licensee and exclusive license. Subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.  

Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use.  At Licensee’s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.

License Property
The Podack Cancer Vaccine (UM97-14) technology shall mean the technology relating to a cell-based vaccine for treating cancer patients utilizes human cancer cells that have been engineered to secrete gp96.  The presently preferred version of the vaccine uses the AD100 human lung adrenocarcinoma cell line transfected with constructs that encode III.A-AI and gp96-Ig (heat shock protein gp96 fused to Fe region of IgGI).  In a presently preferred protocol, NSCLC patients are intradermermally administered several injections of 5×107 vaccine cells each at two week intervals.

Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line “AD100-gp96/III.A”.

Patent Rights shall mean the following United States Patent applications  U.S. provisional patent application serial number 60/075.358 entitled “Modified Heat Shock Protein-antigenic Peptide Complex” and filed on February 20, 1998  U.S. patent application serial number 09 253.439 entitled “Modified Heat Shock Protein-Antigenic Peptide Complex” and filed on February 19, 1999  U.S. patent  application serial number 11/878.460 entitled “Recombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complex” and filed on July 24, 2008  all United States patents and foreign patents and patent applications based on these U.S. applications  all divisionals, continuations of the foregoing  and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358.  U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.  â€œPatent Rights” shall not include Excluded Patent Rights.

Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.

Field of Use
Field of Use is for treating cancer patients and shall mean all human healthcare and research applications.

IPSCIO Record ID: 279370

License Grant
Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license, including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in the Territory excluding Canada; and (b) Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in Canada.

The exclusivity of the foregoing license shall be subject to the retained right of Licensors and their respective Affiliates to practice the Licensor Technology for the purpose of conducting development, manufacture and commercialization of Target Products in the Territory to the extent expressly contemplated by this Agreement.

License Property
HspE7 shall mean any fusion protein containing (a) a human papilloma virus (HPV) E7 antigen, or an antigenic fragment, mutein or conjugate thereof, and (b) a bacterial stress protein, or a fragment, mutein or conjugate thereof, including, in particular and without limitation, that recombinant DNA derived fusion protein containing 638 amino acids, derived from the 65kDa heat shock protein of mycobacterium bovis var. BCG (Hsp65) coupled at the C-terminus to the E7 protein of human papilloma virus (HPV) type 16.  HspE7 includes nucleic acid sequences and vectors and host cells containing nucleic acid sequences encoding such proteins contained therein.

Licensor Technology shall mean the Licensor Know-How and the Licensor Patent Rights..
Licensor Patent Rights shall mean all Patents that Licensor  Controls as of the Execution Date or during the Term, including, without limitation, Patents that claim Licensor Inventions and/or Joint Inventions, which, in the absence of the license granted to Licensee under this Agreement, would be infringed by the making, using, selling, offer for sale or importation of Target Products in the Territory.  The Agreement lists all Licensor Patent Rights existing as of the Execution Date (Base Patents).

US Patent #6,338,952 – Stress proteins and uses therefor
US Patent #6,335,183 – Stress proteins and uses therefor

Field of Use
HspE7 targets a broad spectrum of human papillomavirus ('HPV') related diseases.

IPSCIO Record ID: 230777

License Grant
Licensor hereby grants to Licensee the exclusive license right to use the Subject Technology, including, without limitation, the right to make, have made, use, offer for sale, sell, and import any and all products, methods and services utilizing the Subject Technology and/or the Intellectual Property applicable to the Subject Technology.
License Property
The patents are for Chimeric antibodies comprising antigen binding sites and B and T cell epitopes, and,  Immunization of infants.

The right is for a proprietary immunotherapy platform technology.

Field of Use
The agreement is for all possible fields of use.

IPSCIO Record ID: 369311

License Grant
Licensor of the Netherlands grants to Licensee of Germany a license under the Licensor Technology  to use, import, develop, market and sell and have used, imported, developed, marketed and sold product in the Field in the NA Territory and the ROW Territory.

This agreement includes a non-exclusive grant back to Licensor by Licensee.

License Property
Licensor has technology related to, inter alia, the development of BLP25.

The Product means BLP25.

BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.

MUC1 means cancer associated mucin-1.

L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.

Field of Use
BLP25 Liposome Vaccine (L-BLP25) is currently in development for the treatment of non-small cell lung cancer (NSCLC).  Licensee will take over administrative and financial responsibility for the development and commercialization of L-BLP25, including the planned phase 3 trial in NSCLC

The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 239011

License Grant
Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor), royalty-bearing license in the Field, including the right to grant sublicenses, under the Licensor Patent Rights, the Licensor ownership interest in Joint Patent Rights, Licensor Know-How and Licensor Inventions to make, have made, have used, sell, have sold, offer for sale, and import Licensed Products in the Field. Licensee shall not make, use, sell market or promote Licensed Product for use outside the Field. Where the Licensor Patent Rights are themselves licensed from a Third Party, Licensors license shall take the form of a sublicense.
License Property
Licensor Patent Rights shall mean

(a) the patent and patent applications listed, which shall be updated by Licensor as appropriate from time to time, all patent applications heretofore or hereafter filed or having legal force in any country owned by or licensed to Licensor or to which Licensor otherwise acquires rights, which claim a composition, method or process for biologics or technology, including, but not limited to, cells, cell lines, genes, peptides and proteins which are necessary or useful to practice any process or method related to, or to make, use or sell any Licensed Product in the Field, including Inventions, together with any and all patents that have issued or in the future issue therefrom, including utility, model and design patents and certificates of invention, and

(b) all divisionals, continuations, continuations-in-part, continued prosecution applications, requests for continued examination, reissues, renewals, extensions or additions to any such patents and patent applications; all of Section (a) and this Section (b) of this paragraph to the extent and only to the extent that Licensor hereafter will have the right to grant licenses, immunities or other rights thereunder, and any foreign counterparts to those patents and patent applications, and currently consisting of the Licensor Patent Rights described hereto.

(c) Patents and patent applications licensed to Licensor by a Third party or to which Licensor otherwise acquires rights after the effective date of this Agreement shall become part of the Licensor Patent Rights to the extent that Licensor has the right to grant licenses to Licensee in the Field and only to the extent that Licensor is able to do so on economic terms substantially similar to the economic terms of its primary licenses from third parties as of the effective date.

Licensee Patent Rights
1. 'Polypeptides and Polynucleotides From Coagulase-Negative Staphylococci'
U.S. provisional application 60/098,443 filed 8-31-98 and refiled to add additional subject matter as 60/117,119 on 1-25-99. These provisional applications were converted to U.S. application 09/386,962 filed August 31, 1999, and filed as PCT/US99/19728.  (Licensed exclusively to Licensor by The Texas A&M University System (TAMUS) and BioResearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

2. 'Multicomponent Vaccines'
U.S. provisional Application 60/098,439 filed 8-31-98. This was converted to U.S. application 09/386,959 and PCT/US99/19727 on August  31, 1999. (Licensed exclusively to Licensee by The Texas A&M University System (TAMUS) and Bioresearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14.  No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

3. 'Fibrinogen Binding Proteins From Staphylococcus aureus'
U.S. provisional application filed 11-26-97 as 60/066,815 abandoned in favor of 'Extracellular Matrix-Binding Proteins From Staphylococcus aureus to add additional information, filed 8-31-98 as 60/098,427 converted 11-25-98 to 09/200,650. PCT /US98/25246 was filed 11-25-98.  (Licensed exclusively to Licensee by The Texas A&M University System (TAMUS) and BioResearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

4. 'Fibronectin Binding Protein Compositions and Methods of Use'
U.S. provisional application filed 1-21-97 as 60/036,139, converted 1-21-98 to 09/010,317; PCT filed 1-21-98 as PCT/US98/01222. (Licensed  exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. . The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

5. 'Collagen Binding Protein Compositions and Methods of Use'
U.S. provisional application 60/017,678 filed 5-16-96 converted 5-14-97 to 08/856,253; PCT/US97/08210 filed 5-14-97. (Licensed exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

6. 'S. aureus Fibrinogen Binding Protein Gene'
U.S. application 08/293,728 filed 8-22-94, issued as U.S. patent 6,008,341 on 12-28-99; Div. App. 09/421,868 was filed 10-19-99 and another divisional application was filed 10-5-00. (Licensed exclusively to Licensor by BRI. BRI reserves the right to use this technology for noncommercial research and educational purposes.)

7. 'MHC II Analog From Staphylococcus aureus'
U.S. application filed 5-24-94 as 08/248,021 and issued 7-15-1997 as U.S. patent 5,648,240. (Licensed exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

8. 'Fibronectin Binding Peptide'
Filings SE 90 2617 filed 8-10-90; U.S. 846,995 filed 6-8-92 now abandoned; U.S. 55,783 filed 5-3-93 now abandoned, U.S. 234,622 filed 4-28-94 issued as U.S. patent 5,440,014 on 8-8-95. (Nonexclusively from Magnus Hook.)

9. 'Fibronectin Binding Protein As Well As Its Preparation'
Filings SE 89 1687 filed 5-11-89; U.S. 520,808 parent filed 5-9-90 issued as U.S. patent 5,175,096 on 12-29-92; U.S. divisional 974,181 filed 11-10-92 now abandoned; U.S. continuation 340,458 filed 11-14-94 issued as U.S. patent 5,652,217, 'Fibronectin Binding Protein' on 7-29-97; U.S. divisional 725,492 filed on 10-4-96 issued as U.S. patent 5,840,846, 'Fibronectin Binding Protein As Well As Its Preparation' on 11-24-98. (Nonexclusively from Magnus Hook.)

10. 'Fibronectin Binding Protein As Well As Its Preparation'
Filings SE 87 2272 filed 6-1-87; U.S. parent 201,028 filed 6-1-88 now abandoned; U.S. continuation 746,087 filed 8-12-91 now abandoned; U.S. continuation 937,817 filed 1-22-93 issued as U.S. patent 5,320,951 on 6-14-94; U.S. divisional 259,000 filed 6-13-94 issued as U.S. patent 5,571,514 'Fibronectin Binding Protein As Well As Its Preparation' on 11-5-96; U.S. divisional 729,767 filed 10-7-96 issued as U.S. patent 5,770,702 'Fibronectin Binding Protein As Well As Its Preparation' on 6-23-98. (Nonexclusively from Magnus Hook.)

11. 'Collagen Binding Protein As Well As Its Preparation'
U.S. application 861,804 filed 8-21-92 now abandoned; U.S. continuation 447,031 filed 5-22-95 issued as U.S. patent 5,851,794 on 12-22 98. (Nonexclusively from Magnus Hook.)

12. 'Method for Prophylactic Treatment of the Colonization of a S. aureus Bacterial Strain By Cell Surface Protein With Fibronectin and Fibrinogen Binding Ability'
Filings SE 8402938 filed 5-30-84; U.S. parent 840,580 filed 1-21-86, now abandoned; U.S. continuation 801,593 filed 12-5-91 and issued as U.S. Patent 5,189,015 on 2-23-93. (Nonexclusively from Magnus Hook.)

13. 'Bacterial Cell surface Protein with Fibronectin, Fibrinogen, Collagen and Laminin Binding Ability, Process for the Manufacture of the Protein and Prophylactic Treatment'
Filings U.S. 06/840,580 filed as PCT/SE85/00227 on 5-30-85; U.S. continuation 07/801,593 filed 12-5-91, now U.S. Patent 5,189,015; U.S. divisional 07/977,151 filed 11-16-92; U.S. continuation 08/118,697 filed 9-10-93 and issued as U.S. Patent 5,980,908 on 11-9-99. (Nonexclusively from Magnus Hook.)

Licensed Product shall mean active human vaccines containing MSCRAMM(TM) proteins derived from S. aureus or S. epidermidis, within the Field the manufacture, use or sale of which, but for the license granted herein, would infringe at least one Valid Claim of Licensor Patent Rights, or utilize Licensor Know-How.

Field of Use
Field shall mean human vaccines for containing MSCRAMM(TM) proteins derived from S. aureus and S. epidermidis for the prevention of S. aureus and S. epidermidis infections, provided, however that the Field shall exclude the use of MSCRAMM(TM) proteins or such vaccines to stimulate antibody titer in plasma donors whose plasma is collected for the purpose of developing and commercializing products containing plasma derived immunoglobulin.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.